Oncternal Therapeutics (ONCT) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 4:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abiraterone, accretion, accrual, accuracy, adaptive, administered, antitumor, apalutamide, arrangement, ASC, ATM, Bayesian, body, BOIN, broker, clarify, CODM, cohort, confirm, darolutamide, dealer, declared, detailed, director, disaggregated, doubt, effort, entirety, enzalutamide, exceed, exclude, expedient, expended, formatted, free, gain, Inline, interaction, Interactive, Interval, introduce, invoice, invoiced, issuer, larger, length, mechanism, mediated, mg, modified, moiety, monotherapy, negotiation, NTD, orally, Page, par, passed, percentage, permit, PFS, population, practical, preliminary, prepayment, proportionately, protein, reconciliation, recovered, reduction, regularly, remove, reproducible, retention, retrospectively, robust, ROR, salary, segment, senior, shareholder, short, survival, temporary, toxicity, uncollectible, underserved, understanding, uneven, waiver, withholding, XBRL

Removed: AbbVie, account, accounted, accurately, acquisition, aforementioned, alter, Anderson, announced, appeal, application, area, assessment, assured, bear, began, Biotec, BTK, cGMP, CIRLL, CIRM, Cirmtuzumab, closure, commercialized, commitment, committed, conducted, considerable, covering, cure, deducted, degrader, delisting, deprioritized, designated, determination, distinct, efficacy, eligible, encounter, enroll, enrollment, epitope, escalation, Ewing, exhaust, expenditure, explore, failure, FDA, filing, forecasted, functionally, gene, half, hematologic, holding, implement, important, impose, initiated, Institute, invasion, inventory, investigation, led, Lentigen, letter, lymphoid, MD, Medicine, Miltenyi, modestly, monitor, notification, obligation, October, point, processing, project, prosecution, recently, recognition, recommended, recoverable, refundable, regain, Regenerative, remedy, reprioritized, requiring, RNA, sarcoma, select, selective, show, solicitation, stopped, subleased, subsequent, suspend, threshold, tool, transcription, unforeseen, utilizing, valid, validate, variation

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ONCT transcripts

ONCT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

In connection with the Quarterly Report on Form 10-Q of Oncternal Therapeutics, Inc. (the “Company”) for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James B. Breitmeyer, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James B. Breitmeyer

President and Chief Executive Officer

(Principal Executive Officer)

Dated: May 9, 2024

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.